TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27714970

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed cow's milk protein formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intact cow's milk protein formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal T1D status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regional feeding patterns
Number of subjects: 0
Study: 26259133

Group type: EXPERIMENTAL
Intervention: High-Carbohydrate (HC) meal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-Fat (HF) meal
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: GH therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (OC) group with HC and HF meals
Number of subjects: 28
Study: 23447647

Group type: EXPERIMENTAL
Intervention: Intensive room heating (mean temperature 24.2 ± 1.7°C)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Weak room heating (mean temperature 13.9 ± 3.3°C)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Intensive room heating
Number of subjects: 146
Study: 21669585

Group type: EXPERIMENTAL
Intervention: Liquid fish oil (2x10%, 40%, and 100%)
Number of subjects: 100

Group type: COMPARATOR
Intervention: 100% extra light olive oil
Number of subjects: 100
Study: 19564806

Group type: EXPERIMENTAL
Intervention: Above-elbow posterior fiberglass slab
Number of subjects: 50

Group type: COMPARATOR
Intervention: Collar and cuff immobilization
Number of subjects: 50
Study: 16125357

Group type: EXPERIMENTAL
Intervention: 6-week smoking cessation program plus Internet-assisted instruction (IAI) program
Number of subjects: 77

Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 77
Study: 15517622

Group type: EXPERIMENTAL
Intervention: Willow bark extract (240 mg salicin/day)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Diclofenac (100 mg/day)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 11709562

Group type: EXPERIMENTAL
Intervention: FC/FO (5‐FU/folinic acid combined with alternating irinotecan and oxaliplatin)
Number of subjects: 62

Group type: COMPARATOR
Intervention: OC (oxaliplatin and irinotecan)
Number of subjects: 62
Study: 9146769

Group type: EXPERIMENTAL
Intervention: Omeprazole plus amoxycillin
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Omeprazole plus clarithromycin
Number of subjects: 287
Study: 8198064

Group type: EXPERIMENTAL
Intervention: Ascorbic acid supplementation (500 mg, three times a day) for 5 of the 10 weeks
Number of subjects: 25

Group type: COMPARATOR
Intervention: Typical Western diet
Number of subjects: 25

Group type: COMPARATOR
Intervention: Diet with predicted poorly bioavailable iron
Number of subjects: 25
Study: 3281542

Group type: EXPERIMENTAL
Intervention: Ventilation tubes (grommets)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group without ventilation tubes
Number of subjects: 115
Study: 29982870

Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion chemotherapy (HAIC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 58
Study: 26544615

Group type: EXPERIMENTAL
Intervention: Evidence-based decision support for depression treatment
Number of subjects: 289
Study: 24213308

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CPH)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CyA)
Number of subjects: 38
Study: 23989915

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) 2-3 mg/kg per day
Number of subjects: 72

Group type: COMPARATOR
Intervention: Mesalazine 3.2 g per day
Number of subjects: 72
Study: 21256483

Group type: EXPERIMENTAL
Intervention: Laparotomy with barrier
Number of subjects: 694

Group type: COMPARATOR
Intervention: Laparotomy without barrier
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Laparoscopy with barrier
Number of subjects: 694

Group type: COMPARATOR
Intervention: Laparoscopy without barrier
Number of subjects: 694
Study: 19270470

Group type: EXPERIMENTAL
Intervention: Day clinic treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 55
Study: 16549463

Group type: EXPERIMENTAL
Intervention: CLA-diet rich in CLA (4.7 g/d of c9,t11- and t10,c12-CLA isomers in equal amounts)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: VA-diet rich in VA (3.6 g/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: C-diet, a control diet with a low content of VA and CLA
Number of subjects: 60
Study: 14703736

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol supplementation (500 IU/day)
Number of subjects: 104

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104
Study: 11070960

Group type: EXPERIMENTAL
Intervention: Sevoflurane in Air:O2
Number of subjects: 920

Group type: COMPARATOR
Intervention: Sevoflurane in N2O:O2
Number of subjects: 920
Study: 9057190

Group type: EXPERIMENTAL
Intervention: Pancreatin (Creon) supplementation
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 8420411

Group type: EXPERIMENTAL
Intervention: Heparin (25 U/kg) administered intravenously 10 min before challenge
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nebulized heparin (20,000 units) administered 10 min before challenge
Number of subjects: 25
Study: 3310589

Group type: EXPERIMENTAL
Intervention: Moricizine HCl therapy
Number of subjects: 81
Study: 29862568

Group type: EXPERIMENTAL
Intervention: Psychological intervention therapy combined with routine medications
Number of subjects: 156

Group type: COMPARATOR
Intervention: Routine medication
Number of subjects: 156
Study: 26585394

Group type: EXPERIMENTAL
Intervention: ΔMTTp3-6 (perfusion change between 3 and 6 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ΔMTT6-24 (perfusion change between 6 and 24 hours)
Number of subjects: 0
Study: 24921074

Group type: EXPERIMENTAL
Intervention: Smartphone diary
Number of subjects: 47

Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 47
Study: 24378099

Group type: EXPERIMENTAL
Intervention: CIK cells transfusion
Number of subjects: 128

Group type: COMPARATOR
Intervention: Regular follow-up
Number of subjects: 128
Study: 15729225

Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg orally
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 12893326

Group type: EXPERIMENTAL
Intervention: OXY‐TDS 3.9 mg/day
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: TOL‐LA 4 mg/day
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study: 9467472

Group type: EXPERIMENTAL
Intervention: Piroxicam FDDF (40 mg sublingual)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diclofenac sodium (75 mg intramuscular)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Piroxicam FDDF
Number of subjects: 80

Group type: COMPARATOR
Intervention: Diclofenac sodium
Number of subjects: 80
Study: 7874912

Group type: EXPERIMENTAL
Intervention: Critical care medicine elective consisting of orientation, interactive conferences, technical skills laboratories, daily rounds, and patient-care experience.
Number of subjects: 0
Study: 2089356

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (2 x 200 mg/day for 6 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (6-week period)
Number of subjects: 12
Study: 512665

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 30755066

Group type: EXPERIMENTAL
Intervention: STOP Dating Violence intervention
Number of subjects: 317

Group type: COMPARATOR
Intervention: Website containing information about dating violence
Number of subjects: 317

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 317
Study: 30219027

Group type: COMPARATOR
Intervention: Scalp nerves block with 15 ml bupivacaine 0.5%, 15 ml lidocaine 2%, in 1:400000 epinephrine (Group LA)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Scalp nerves block with 15 ml bupivacaine 0.5%, 15 ml lidocaine 2%, in 1:400000 epinephrine plus 15 IU/ml Hyaluronidase (Group H)
Number of subjects: 64
Study: 27308644

Group type: EXPERIMENTAL
Intervention: Standard therapy (esomeprazole 20 mg, twice daily)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Double-dose therapy (esomeprazole 40 mg, twice daily)
Number of subjects: 145
Study: 25327949

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 29
Study: 23656302

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 378

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 378
Study: 20737811

Group type: EXPERIMENTAL
Intervention: Injectable diacetylmorphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 60
Study: 18062784

Group type: EXPERIMENTAL
Intervention: Electronic decision support system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paper documentation
Number of subjects: 0
Study: 16009293

Group type: EXPERIMENTAL
Intervention: Kiosk-based tailoring intervention (n = 70)
Number of subjects: 144
Study: 12464464

Group type: EXPERIMENTAL
Intervention: Amisulpride (400-1,000 mg/day)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Risperidone (4-10 mg/day)
Number of subjects: 309
Study: 10515677

Group type: EXPERIMENTAL
Intervention: 17betaE-D
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: CEE-N
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 8624228

Group type: EXPERIMENTAL
Intervention: Parodontax toothpaste
Number of subjects: 60

Group type: COMPARATOR
Intervention: New toothpaste
Number of subjects: 60
Study: 2290711

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (Cef) 2 g daily infusion
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (P) 2 g daily infusion
Number of subjects: 44
Study: 6105713

Group type: EXPERIMENTAL
Intervention: Guanfacine combined with clorexolone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Methyldopa combined with clorexolone
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 33
Study: 31961463

Group type: EXPERIMENTAL
Intervention: Metformin plus megestrol acetate (MA) - MA (160 mg orally, daily) plus metformin (500 mg orally, three times a day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Megestrol acetate (MA) alone - MA (160 mg orally, daily)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metformin plus MA in AEH patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metformin plus MA in non-obese AEH patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Metformin plus MA in insulin-sensitive AEH patients
Number of subjects: 150
Study: 31831076

Group type: EXPERIMENTAL
Intervention: Interactive mobile messaging alert system
Number of subjects: 450

Group type: COMPARATOR
Intervention: Control group (usual antenatal care services)
Number of subjects: 450
Study: 28231265

Group type: EXPERIMENTAL
Intervention: SCT-based intervention
Number of subjects: 170

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 170
Study: 25872747

Group type: EXPERIMENTAL
Intervention: Time to site opening
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Time to ethics and regulatory approval
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Time to first randomisation
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Recruitment rates
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Time to electronic data collection (EDC)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Time for initial SAE submission to sponsor
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Time to submit final reports
Number of subjects: 322
Study: 24225216

Group type: EXPERIMENTAL
Intervention: PCT monitoring in guiding the use of antibiotics group (PCT group, n=42)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Regular antibiotic therapy group (RAT group, n=40)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups (PCT and RAT)
Number of subjects: 82
Study: 21321243

Group type: EXPERIMENTAL
Intervention: Maternal plasma with elevated ratio of ApoCIII to ApoCII
Number of subjects: 311
Study: 19692221

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg/day for 3 months followed by 100 microg/day for 9 months
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg/day for 9 months
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250 microg/day for 3 months
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 17416150

Group type: EXPERIMENTAL
Intervention: ACBT with postural drainage (ACBT-PD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Active cycle of breathing technique (ACBT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Flutter
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ACBT
Number of subjects: 36
Study: 15601349

Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg x kg(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11377651

Group type: EXPERIMENTAL
Intervention: Local activation of low-dose ifosfamide using encapsulated genetically modified allogeneic cells delivered by supraselective angiography
Number of subjects: 14

Group type: COMPARATOR
Intervention: Historic controls (not specified in detail)
Number of subjects: 14
Study: 9517370

Group type: EXPERIMENTAL
Intervention: Gemfibrozil, 600 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lovastatin, 40 mg daily
Number of subjects: 0
Study: 8278467

Group type: EXPERIMENTAL
Intervention: Siltex textured inflatable implant
Number of subjects: 56

Group type: COMPARATOR
Intervention: Smooth inflatable implant
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Povidone-iodine irrigation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 56
Study: 2662695

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (3 g/day)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 4581246

Group type: EXPERIMENTAL
Intervention: Benapryzine
Number of subjects: 0
Study: 31765030

Group type: EXPERIMENTAL
Intervention: nCPAP
Number of subjects: 93

Group type: COMPARATOR
Intervention: BiPAP
Number of subjects: 93
Study: 29961442

Group type: COMPARATOR
Intervention: Postal intervention (n=339)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Nurse support (n=346)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Control group (n=338)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: Nurse support plus postal (n=346)
Number of subjects: 1023
Study: 27429374

Group type: EXPERIMENTAL
Intervention: Half-dose group (3 mg/m verteporfin, 83 seconds laser light)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Half-fluence group (6 mg/m verteporfin, 42 seconds laser light)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 26814085

Group type: EXPERIMENTAL
Intervention: NBI-assisted holmium laser resection (NBI-HoLRBt)
Number of subjects: 178

Group type: COMPARATOR
Intervention: White light imaging assisted transurethral resection (WLI-TURBt)
Number of subjects: 178
Study: 24363547

Group type: EXPERIMENTAL
Intervention: Cotrimoxazole Prophylactic Treatment (CPT)
Number of subjects: 1236
Study: 21910334

Group type: EXPERIMENTAL
Intervention: Tangshen Recipe (TR)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Western medicine treatment (insulin and anti-diabetic drugs)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 64
Study: 18452406

Group type: EXPERIMENTAL
Intervention: Intraoral appliance simulating occlusal conditions of shortened dental arches
Number of subjects: 13

Group type: COMPARATOR
Intervention: No intraoral appliance (control)
Number of subjects: 13
Study: 16541242

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 18
Study: 12671470

Group type: EXPERIMENTAL
Intervention: Dorzolamide 2%
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (tear-replacement drops)
Number of subjects: 28
Study: 10871561

Group type: EXPERIMENTAL
Intervention: High-fat, low-fiber diet
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-fat, high-fiber diet
Number of subjects: 22
Study: 8997964

Group type: EXPERIMENTAL
Intervention: Staff education program based on the ENA Core Curriculum
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison group of registered nurses who did not attend the classes
Number of subjects: 20
Study: 1361240

Group type: EXPERIMENTAL
Intervention: Zidovudine treatment
Number of subjects: 35
Study: 6422900

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP), 200 mg orally
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium carbonate or monoamine oxidase (MAO) inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants (TCA) and second-generation antidepressants
Number of subjects: 0
Study: 30544237

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning
Number of subjects: 124

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 124
Study: 29346378

Group type: EXPERIMENTAL
Intervention: Virtual Clinic
Number of subjects: 195

Group type: COMPARATOR
Intervention: Standard Clinic
Number of subjects: 195
Study: 27641088

Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 20

Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 20
Study: 25286703

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided facet joint injection
Number of subjects: 20

Group type: COMPARATOR
Intervention: Blindly administered facet joint block
Number of subjects: 20
Study: 22811444

Group type: EXPERIMENTAL
Intervention: Dark chocolate (85% cocoa, 0.55 g/kg body wt)
Number of subjects: 22

Group type: COMPARATOR
Intervention: White chocolate (control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dark chocolate
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dark chocolate and white chocolate
Number of subjects: 22
Study: 20600400

Group type: EXPERIMENTAL
Intervention: Tablets containing 20% (w/w) HPMC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tablets containing 40% (w/w) HPMC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Tablets with lower concentration of HPMC and higher lactose concentration
Number of subjects: 6
Study: 17646513

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.05% with fentanyl 4 mug/mL and droperidol 25 microg/mL
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.075% with fentanyl 4 mug/mL and droperidol 25 microg/mL
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.1% with fentanyl 4 mug/mL and droperidol 25 microg/mL
Number of subjects: 312
Study: 16286872

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg(‐1) body mass)
Number of subjects: 9
Study: 12670087

Group type: EXPERIMENTAL
Intervention: 1 mg minocycline hydrochloride (Arestin) administered at baseline, three and six months
Number of subjects: 271

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 271
Study: 9619131

Group type: EXPERIMENTAL
Intervention: Exposure to happy facial expressions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to angry facial expressions
Number of subjects: 0
Study: 7654482

Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg once a day for 2 months
Number of subjects: 21
Study: 2486962

Group type: EXPERIMENTAL
Intervention: Elective appendectomy during cesarean section
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (cesarean section without appendectomy)
Number of subjects: 90
Study: 798591

Group type: EXPERIMENTAL
Intervention: Halofenate
Number of subjects: 23

Group type: COMPARATOR
Intervention: Probenecid
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 6965977

Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus adherence in patients with acute respiratory illness and volunteers infected with influenza virus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae adherence in volunteers experimentally infected with influenza virus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae type I adherence in volunteers experimentally infected with influenza virus
Number of subjects: 0
Study: 31684867

Group type: EXPERIMENTAL
Intervention: IV lidocaine bolus 1.5 mg/kg at induction followed by an infusion (1.5 mg/kg/h)
Number of subjects: 90

Group type: COMPARATOR
Intervention: IV esmolol bolus 0.5 mg/kg at induction followed by an infusion (5-15 μg/kg/min)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: IV lidocaine
Number of subjects: 90

Group type: COMPARATOR
Intervention: IV esmolol
Number of subjects: 90
Study: 29608789

Group type: EXPERIMENTAL
Intervention: Adjusted Respecting Choices ACP program
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study: 26679480

Group type: EXPERIMENTAL
Intervention: Budesonide respules via mucosal atomization device (MAD) twice daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Budesonide respules instilled via vertex-to-floor (VF) position twice daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fluticasone nasal spray twice daily
Number of subjects: 32
Study: 25496532

Group type: EXPERIMENTAL
Intervention: Questionnaire for assessing headache burden
Number of subjects: 1202
Study: 23103035

Group type: EXPERIMENTAL
Intervention: Long-term PM(2.5) exposure (3 μg/m(3) increase)
Number of subjects: 3040

Group type: COMPARATOR
Intervention: Short-term PM(2.5) exposure (12 μg/m(3) daily increase)
Number of subjects: 3040
Study: 19762075

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 180
Study: 17496489

Group type: EXPERIMENTAL
Intervention: Trimetazidine, 20 mg three times daily for 12 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 66
Study: 15648728

Group type: EXPERIMENTAL
Intervention: Straight-ahead movements
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Angled movements
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Kinematic analysis
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Planning and control processes
Number of subjects: 2